Hims & Hers (HIMS) Q1 2026 earnings review
International Boom Masks Domestic Decline and Margin Collapse
Despite management's claims of 'pulling away from the field,' Hims & Hers hit a wall in Q1 2026. Total revenue growth decelerated aggressively to just 4% YoY, dragged down by an 8% contraction in the core U.S. business. The bottom line reversed violently from a $49.5M profit a year ago to a $92.1M net loss, hammered by a $33.5M restructuring charge tied to its GLP-1 pivot, a $15M legal settlement, and plunging gross margins (65% vs 73%). While a 969% surge in international revenue saved the top line and strong Q2 guidance suggests a rebound, the costly transition away from high-margin compounded GLP-1s toward branded offerings is currently crushing profitability.
🐂 Bull Case
International revenue surged 969% YoY to $78.2 million, validating the company's aggressive M&A strategy (Zava, Eucalyptus) and proving the platform can scale globally.
Management expects Q2 revenue of $680-$700 million, implying an acceleration to ~26% YoY growth, signaling that Q1's weakness was a transitional trough.
🐻 Bear Case
U.S. Revenue shrank 8% YoY to $530M. If the domestic core cannot re-accelerate, international acquisitions will merely mask a dying domestic engine.
The pivot to branded GLP-1s is destroying the gross margin profile (down 800 bps YoY). Adding a massive spike in Accounts Receivable, earnings quality has materially deteriorated.
⚖️ Verdict: 🔴
Bearish. The narrative of structural acceleration contradicts the data. Reversing U.S. revenue, collapsing margins, and a massive spike in unpaid receivables outweigh the international growth story in the near term.
Key Themes
U.S. Revenue Engine Throws a Rod
Reversing trend. For the first time, U.S. Revenue contracted, falling 8% YoY from $578.7M to $529.9M. This is a staggering break in trend from the 50%+ domestic growth seen throughout 2025. Management's narrative of 'pulling away from the field' in the domestic business is directly contradicted by the numbers. The overall 4% revenue growth was entirely manufactured by the 969% spike in Rest of World revenue ($7.3M to $78.2M).
GLP-1 Strategic Pivot Crushes Margins
Decelerating. The company announced a strategic shift to scale back high-margin compounded GLP-1s in favor of branded GLP-1 medications. The immediate result was a margin bloodbath. Gross margins fell from 73% to 65%. Furthermore, the pivot forced a $33.5M restructuring charge driven by inventory write-downs and third-party costs. The shift toward branded pharma effectively turns Hims & Hers into a lower-margin distributor rather than a high-margin personalized health provider.
Massive Spike in Accounts Receivable
A major red flag exists on the balance sheet: Accounts Receivable exploded from $32.1M at the end of 2025 to $149.6M in Q1 2026. This $117M increase consumed more cash than the company's entire net operating cash flow for the quarter. In a subscription-based business model where customers typically pay upfront, a 365% sequential spike in uncollected revenue demands immediate explanation. It could signal changes in wholesale terms, issues with insurance/B2B collections, or aggressive revenue recognition practices.
International Expansion Hits Scale
Accelerating. The Rest of World segment is now a material driver, generating $78.2 million in Q1 (nearly 13% of total sales). This validates the integration of the Zava and Livewell acquisitions. With the pending Eucalyptus acquisition poised to add Australia and Japan, management's goal of reaching a $1 billion international run rate is mathematically plausible, provided they can absorb the margin drag of integration.
Subscribers Grow, But Monetization Dips
Stable subscriber growth, but decelerating monetization. Total subscribers grew 9% YoY to 2.58 million. However, Monthly Revenue per Average Subscriber fell 6% YoY from $85 to $80. This dilution is likely driven by the rapid influx of international subscribers (who typically monetize at lower rates) and the ongoing transition away from premium-priced compounded weight-loss treatments.
Other KPIs
Stable. Despite the $92.1 million net loss, Free Cash Flow slightly increased YoY from $50.1 million. The company successfully delayed paying its suppliers to offset the massive spike in Accounts Receivable, with Accounts Payable jumping sequentially by over $160 million. While FCF is positive, this working capital dynamic is unsustainable long-term.
Accelerating significantly. G&A more than doubled from $48.6 million in Q1 2025. Even after adjusting for $21.9M in stock-based compensation, $15.0M in legal settlements, and $13.4M in acquisition costs, adjusted G&A nearly doubled to $59.4M. The overhead cost of managing a sprawling, multi-national operation is rapidly eating into operational leverage.
Guidance
Accelerating. The midpoint of $690 million implies ~26% YoY growth (assuming a Q2 2025 base of $545M) and a robust 13% sequential jump from Q1. This guidance puts significant pressure on management to prove that Q1's U.S. revenue decline was a one-time anomaly rather than a structural ceiling.
Decelerating. The implied margin is 5% to 8%, a steep drop from the 15% margin achieved in Q2 2025. This reflects the continued margin drag of lower-margin branded GLP-1 sales and heavy integration costs for international acquisitions.
Accelerating. The full-year guidance (which explicitly excludes the pending Eucalyptus acquisition) was raised and implies ~23% YoY growth. Reaching this target requires flawless execution in scaling the new personalized multi-specialty offerings (like menopause and testosterone) to offset the drag from the GLP-1 transition.
Decelerating margin profile. The midpoint of $312.5 million implies an Adjusted EBITDA margin of 10% to 12%. This is a notable contraction from the 14% margin achieved in FY 2025, confirming that the company has officially exited its margin-expansion phase and entered a heavy, prolonged investment cycle.
Key Questions
U.S. Revenue Contraction
U.S. revenue declined 8% year-over-year this quarter. How much of this contraction was driven by the shift away from compounded GLP-1s versus a slowdown in legacy categories, and what gives you confidence in sequential acceleration for Q2?
Explosion in Accounts Receivable
Accounts Receivable jumped from $32 million to nearly $150 million in a single quarter. In a predominantly direct-to-consumer subscription model, what drove this massive $117 million cash absorption?
Structural Margin Ceiling
With gross margins stepping down 800 basis points year-over-year due to the branded GLP-1 mix, should investors view 65% as the new structural ceiling for gross margins going forward?
Legal and Restructuring Outlook
You recorded a $15 million legal settlement and a $33 million restructuring charge for inventory write-downs. Are the third-party costs and write-downs related to the weight-loss pivot fully ring-fenced in Q1, or should we expect continued bleeding into Q2?